The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
 
Enrique Sanz Garcia
No Relationships to Disclose
 
Jinfeng Zou
Patents, Royalties, Other Intellectual Property - Co-inventor of patent application pending related to detection of HPV circulating cell-free DNA. It is held by the institution and is not royalty generating.
 
Lisa Avery
No Relationships to Disclose
 
Anna Spreafico
Honoraria - Immunocore; Medison
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore; Medison; Merck
Research Funding - Alkermes (Inst); ALX Oncology (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Nubiyota (Inst); Pfizer (Inst); Replimune (Inst); Roche (Inst); Seagen (Inst); SERVIER (Inst); Surface Oncology (Inst); Symphogen (Inst); Treadwell Therapeutics (Inst)
 
John Waldron
No Relationships to Disclose
 
David Paul Goldstein
No Relationships to Disclose
 
Aaron Richard Hansen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Neoleukin Therapeutics (Inst); Pfizer/EMD Serono (Inst); Roche/Genentech (Inst)
 
John Cho
No Relationships to Disclose
 
John R de Almeida
No Relationships to Disclose
 
Andrew Hope
No Relationships to Disclose
 
Ali Hosni
(OPTIONAL) Uncompensated Relationships - Elekta
 
Ezra Hahn
No Relationships to Disclose
 
Bayardo Perez-Ordonez
No Relationships to Disclose
 
Zhen Zhao
Patents, Royalties, Other Intellectual Property - Co-inventor of patent application pending related to detection of HPV circulating cell-free DNA. It is held by the institution and is not royalty generating.
 
Christopher Gareth Smith
Employment - NeoGenomics Laboratories
 
Yangqiao Zheng
No Relationships to Disclose
 
Nitzan Rosenfeld
Employment - Inivata; Storm Therapeutics (I)
Leadership - Inivata
Stock and Other Ownership Interests - Inivata; Storm Therapeutics (I)
Patents, Royalties, Other Intellectual Property - patents and patent applications managed by Inivata and by CRUK
 
Nittusha Singaravelan
No Relationships to Disclose
 
Scott Victor Bratman
Employment - Adela
Leadership - Adela
Stock and Other Ownership Interests - Adela
Patents, Royalties, Other Intellectual Property - Co-inventor and holder of a patent related to circulating tumor DNA detection technology.; Co-inventor of patent application pending related to detection of HPV circulating cell-free DNA. (Inst); Co-inventor of patents related to cell-free DNA methylation analysis technology. (Inst)
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Hookipa Pharma; InterRNA; Janpix; Janssen; Merck; Navire; Oncorus; Relay Therapeutics; Roche; Sanofi; Seagen; Tessa Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)